Oric Pharmaceuticals (ORIC) News Today $9.22 +0.23 (+2.50%) As of 11:31 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Oric Pharmaceuticals Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Cut by WedbushOctober 27 at 9:53 AM | marketbeat.comWedbush Adjusts Price Target on ORIC Pharmaceuticals to $14 From $17, Keeps Outperform RatingOctober 27 at 8:28 AM | marketscreener.comMORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst OptimismOctober 27 at 8:28 AM | finance.yahoo.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Crosses Below 200-Day Moving Average - Here's WhyOctober 27 at 4:09 AM | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average - Should You Sell?October 27 at 3:59 AM | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 13.7% - What's Next?October 26 at 12:39 PM | marketbeat.comOric Pharmaceuticals, Inc. (ORIC) - What Are Brokerages Saying About This Stock?October 24, 2026 | americanbankingnews.comOric Pharmaceuticals, Inc. (ORIC) - What Are Analysts Thinking About This Stock?October 24, 2026 | marketbeat.comORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer TranscriptOctober 23, 2026 | seekingalpha.comOric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer StudyOctober 23, 2026 | marketbeat.comOric Pharmaceuticals, Inc. Presents Potential Best-In-Class Data for Enozertinib in First-Line Nsclc Patients with Egfr Atypical Mutations At Esmo Congress 2026 and Plans to ...October 23, 2026 | marketscreener.comMORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer DataOctober 23, 2026 | rttnews.comORIC Pharmaceuticals, Inc. announces phase 1b enozertinib data and plans for phase 3 Redwood-1 trial in 1H 2027October 23, 2026 | msn.comORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance ...October 23, 2026 | finance.yahoo.comORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate ...October 23, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026October 23, 2026 | globenewswire.comORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialOctober 23, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Stock: Insider Dominic Piscitelli Sells 14,000 SharesOctober 22, 2026 | insidertrades.comOric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockOctober 21, 2026 | marketbeat.comORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026October 20, 2026 | finance.yahoo.comORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026October 19, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% After Analyst UpgradeOctober 17, 2026 | americanbankingnews.comOric Pharmaceuticals (NASDAQ:ORIC) Shares Climb 8.5% on Analyst UpgradeOctober 15, 2026 | marketbeat.comOric Pharmaceuticals (NASDAQ:ORIC) Price Target Raised to $26.00October 14, 2026 | marketbeat.comDoes ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?October 8, 2026 | finance.yahoo.comORIC(R) Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 6, 2026 | marketscreener.comMOric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.6% - Here's What HappenedOctober 6, 2026 | marketbeat.comORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical DevelopmentOctober 5, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) Coverage Initiated by Analysts at Leerink PartnersOctober 5, 2026 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comOric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 13,400 Shares of Company StockSeptember 30, 2026 | insidertrades.comOric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $181,302.00 in StockSeptember 29, 2026 | marketbeat.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18September 29, 2026 | marketbeat.comBTIG initiates coverage of ORIC Pharmaceuticals at buySeptember 24, 2026 | msn.comBTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price TargetSeptember 23, 2026 | marketscreener.comMORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 LaunchSeptember 15, 2026 | insidermonkey.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comDominic Piscitelli Sells 77,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) StockAugust 29, 2026 | insidertrades.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)August 5, 2026 | theglobeandmail.comORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational UpdatesAugust 3, 2026 | globenewswire.comORIC Pharmaceuticals: Royalty-Free Phase 3 Economics Strengthen The Bull CaseJuly 21, 2026 | seekingalpha.comORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026July 20, 2026 | globenewswire.comORIC Pharmaceuticals Inc 4TZJuly 16, 2026 | morningstar.comMORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical ...July 15, 2026 | markets.businessinsider.comORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with BayerJuly 14, 2026 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comORIC gains as Stifel resumes at buy on upcoming Pfizer readoutJune 13, 2026 | msn.com Oric Pharmaceuticals Media Mentions By Week Oric Pharmaceuticals Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORIC News Sentiment▼0.030.69▲Average Healthcare News Sentiment Oric Pharmaceuticals News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORIC Articles This Week▼234▲ORIC Articles Average Week Oric Pharmaceuticals Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views2,353-1% Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PTC Therapeutics News Today Scholar Rock News Today Oruka Therapeutics News Today CRISPR Therapeutics News Today Erasca News Today Travere Therapeutics News Today Edgewise Therapeutics News Today Dianthus Therapeutics News Today Tango Therapeutics News Today Telix Pharmaceuticals News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Oric Pharmaceuticals dated 10/27/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
